Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

BACKGROUND: ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging studies. Trastuzumab typically becomes ineffective in the case of this disease a...

Descripción completa

Detalles Bibliográficos
Autores principales: Durcker, Arik, Yoo, Byong Hoon, Khan, Iman Aftab, Choi, Dongsic, Montermini, Laura, Liu, Xiaoyang, Jovanovic, Sanja, Younis, Tallal, Rosen, Kirill V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541295/
https://www.ncbi.nlm.nih.gov/pubmed/33023655
http://dx.doi.org/10.1186/s13058-020-01342-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541295/
https://www.ncbi.nlm.nih.gov/pubmed/33023655
http://dx.doi.org/10.1186/s13058-020-01342-2

Ejemplares similares